Company profile
Avistone operates two wholly-owned subsidiaries:

Beijing Purun'ao Biotechnology Co.,Ltd. incorporated in 2012, and;

Avistone Pharmaceuticals Biotechnology Co.,Ltd. incorporated in 2018。

 

Our Company is focused on health services industry, aiming to offer high-quality medical products to patients. Our main areas of research are "best in class" and "first in class" innovative drugs, principally for the treatment of tumors. Aiming to contribute to the development of national pharmaceutical industry by accelerating industrialization of innovative drugs, we develop innovative drugs with innovative business models, and has established a complete innovative drug research and development platform of international level through cooperation.

  • Mission
    Providing high-quality, innovative drugs Making quality life accessible to patients
  • Vision
    Become a trusted biopharmaceutical company serving human health with continuous innovation.
Social Responsibility
Team introduction
Wu Yilong
Professor
Jiang Tao
Professor
Shi Hepeng
Founder, Chairman and CEO of Avistone
Zhang Peilong
Chief Technology Officer, Avistone
David Chung
Chief Business Officer, Avistone
Kevin Schaab, Ph.D.
VP, Non-Clinical Development & CMC
Shi Hepeng
Founder, Chairman and CEO of Avistone
Dr. Lu Hongbo
Director
Dr. Liu Weidong
Director
Dr. Ricky Sun
Director
Zheng Jiaqi, Director
Director
Development history
2022

• The 10th anniversary of Avistone Biotechnology

• The NDA application of Vebreltinib has been officially accepted by the China CDE and approved for priority review

• Vebreltinib received orphan drug designation from the U.S. FDA

• The patient enrollment was formally completed for the glioma indication of Vebreltinib

• The discovery of the key driver of the malignant progression of glioma and the development and application of new small molecule inhibitors of Vebreltinib won the first prize of "Entrepreneurship Award" issued by the China Invention Association

• The US IND application of andatinib (PLB1004) is officially opened, which is a key step to open up the global market

• The ANS01 program identified candidate compounds that address the activation circle resistance of type Ib c-Met inhibitors, as well as common Met gene abnormalities, including exon 14 skipping mutations and gene amplification

2021

Vebreltinib received recognition for breakthrough therapy on March 2021 from Drug Approval Center under National Medical Products Administration, with tentative indication being non-small cell lung cancer with c-MET expressed region 14 mutation; patent approval for Andatinib (PLB1004) compound; Avistone completed Series A funding, raising more than $200 million.

2020

Clinical trial approval and launch of clinical trial for Andatinib (PLB1004).

2019

Launch of Vebreltinib for Phases II critical registration for clinical trials for non-small cell lung cancer indication; IND filing for Andatinib (PLB1004).

2018

Inception of Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.; launch of Vebreltinib GBM Phases II/III critical registration for clinical trials; patent approved for Vebreltinib precision treatment for glioma; operating mechanism and results of the Phase I clinical trial for Vebreltinib treatment for glioma published on the top international medical publication "Cell"; precision treatment of Vebreltinib for glioma named "China's Top 10 Advances in Life Sciences in 2018" by China Association for Science and Technology.

2016

First example of patient with non-small cell lung cancer indication included in Vebreltinib group; first example of patient with glioma indication included in Vebreltinib group; major project support for Vebreltinib under "Major Drug Innovation of the Thirteenth Five-Year Plan".

2015

Clinical trial officially commenced for Vebreltinib following approval. Dr. Shi Hepeng nominated for "Beijing Leading Innovation & Entrepreneurial Talent Support Plan" by Beijing Municipal Human Resources and Social Security Bureau.

2014

Dr. Shi Hepeng named "Beijing 100 Leading S & T Talents Development Project" by Beijing Municipal Science and Technology Commission.

2013

Patent approval and IND filing for Vebreltinib.

2012

Inception of Beijing Purun'ao Biotechnology Co.,Ltd.

Patient care
Here comes the ranking list! Unveiling the Top 10 finalists in biomedical field for 2022 Zhongguancun International Frontier Technology Innovation Competition
2022-09-15 00:00:00.000
On the afternoon of September 15, the final of 2022 Zhongguancun International Frontier Science and Technology Innovation Competition in the field of biomedicine was held in Zhongguancun Life Science Park, Changping District. 10 hard technology enterprises stood out from the final and successfully entered the TOP10 in the field of biomedicine in the frontier competition.
View Details
Accolades
2021/2022
Vebreltinib received recognition for breakthrough therapy by National Medical Products Administration
Vebreltinib received orphan drug certification from FDA
2018
Vebreltinib precision treatment for glioma named "China's Top 10 Advances in Life Sciences in 2018" by China Association for Science and Technology
Top international medical publication "Cell"
Publication of operating mechanism and results of Phase I clinical trial for Vebreltinib treatment for glioma
2016
Purun'ao became a member of the inaugural batch of companies in Beijing Biopharmaceutical Industry Breakthrough Development Project (also known as G20 Project)
2014
Dr. Shi Hepeng and his research team selected for "100 Leading Science and Technology Talents Development Project of Beijing".
2015
Dr. Shi Hepeng nominated for "Leading Innovation and Entrepreneurial Talent Support Plan" by Beijing Municipal Human Resources and Social Security Bureau.